JP2013541944A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013541944A5 JP2013541944A5 JP2013529675A JP2013529675A JP2013541944A5 JP 2013541944 A5 JP2013541944 A5 JP 2013541944A5 JP 2013529675 A JP2013529675 A JP 2013529675A JP 2013529675 A JP2013529675 A JP 2013529675A JP 2013541944 A5 JP2013541944 A5 JP 2013541944A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chimeric antibody
- subject
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38676410P | 2010-09-27 | 2010-09-27 | |
| US61/386,764 | 2010-09-27 | ||
| PCT/EP2011/066791 WO2012041863A1 (en) | 2010-09-27 | 2011-09-27 | Compositions and methods for treating neoplasia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013541944A JP2013541944A (ja) | 2013-11-21 |
| JP2013541944A5 true JP2013541944A5 (https=) | 2014-11-13 |
| JP5946459B2 JP5946459B2 (ja) | 2016-07-06 |
Family
ID=44675608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529675A Expired - Fee Related JP5946459B2 (ja) | 2010-09-27 | 2011-09-27 | 腫瘍形成（ｎｅｏｐｌａｓｉａ）を治療するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9115192B2 (https=) |
| EP (1) | EP2621947A1 (https=) |
| JP (1) | JP5946459B2 (https=) |
| KR (1) | KR20140016240A (https=) |
| CN (1) | CN103459420B (https=) |
| AU (1) | AU2011310664B2 (https=) |
| BR (1) | BR112013007327A2 (https=) |
| CA (1) | CA2812644A1 (https=) |
| IL (1) | IL225483A0 (https=) |
| MX (1) | MX2013003561A (https=) |
| SG (1) | SG189095A1 (https=) |
| WO (1) | WO2012041863A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI718086B (zh) | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
| JP6488520B2 (ja) * | 2013-08-20 | 2019-03-27 | 国立研究開発法人科学技術振興機構 | ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法 |
| ES2863500T3 (es) | 2015-04-10 | 2021-10-11 | Capsugel Belgium Nv | Formulaciones lipídicas de acetato de abiraterona |
| TWI728975B (zh) * | 2015-05-12 | 2021-06-01 | 英屬維爾京群島商遠東超級實驗室有限公司 | 鑒定對腫瘤具有直接抑制作用的干擾素的方法及其用途 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US7959915B2 (en) | 2003-03-12 | 2011-06-14 | Tufts University | Inhibitors of extracellular Hsp90 |
| US7780963B2 (en) * | 2004-10-25 | 2010-08-24 | Merck & Co., Inc. | Anti-ADDL antibodies and uses thereof |
-
2011
- 2011-09-27 EP EP11760802.6A patent/EP2621947A1/en not_active Withdrawn
- 2011-09-27 MX MX2013003561A patent/MX2013003561A/es not_active Application Discontinuation
- 2011-09-27 AU AU2011310664A patent/AU2011310664B2/en not_active Ceased
- 2011-09-27 CN CN201180056980.1A patent/CN103459420B/zh not_active Expired - Fee Related
- 2011-09-27 SG SG2013022249A patent/SG189095A1/en unknown
- 2011-09-27 KR KR1020137010742A patent/KR20140016240A/ko not_active Withdrawn
- 2011-09-27 JP JP2013529675A patent/JP5946459B2/ja not_active Expired - Fee Related
- 2011-09-27 WO PCT/EP2011/066791 patent/WO2012041863A1/en not_active Ceased
- 2011-09-27 BR BR112013007327A patent/BR112013007327A2/pt not_active IP Right Cessation
- 2011-09-27 CA CA2812644A patent/CA2812644A1/en not_active Abandoned
-
2013
- 2013-03-12 US US13/797,194 patent/US9115192B2/en not_active Expired - Fee Related
- 2013-03-24 IL IL225483A patent/IL225483A0/en unknown
-
2015
- 2015-08-21 US US14/832,604 patent/US9328161B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013541944A5 (https=) | ||
| ES2786083T3 (es) | Anticuerpos terapéuticos CD47 | |
| ES2829206T3 (es) | Moduladores novedosos y procedimientos de uso | |
| JP2010534237A5 (https=) | ||
| JP2013502204A5 (https=) | ||
| JP2008541711A5 (https=) | ||
| US10441587B2 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| JP2010523541A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| JP2013515013A5 (https=) | ||
| CN113045660A (zh) | 与cd8的抗原结合构建体 | |
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| JP2014511179A5 (https=) | ||
| RU2007147596A (ru) | Моноклональные антитела и одноцепочечные фрагменты антител против клеточно-поверхностного специфического для простаты мембранного антигена | |
| MX348577B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| CA3027120A1 (en) | Anti-ige antibodies | |
| JP2011507852A5 (https=) | ||
| CO6241160A2 (es) | Anticuerpos anti-cd44 quiméricos y humanizados que median la citotoxicidad de celulas de cancer | |
| JP2013506686A5 (https=) | ||
| JP2018508229A5 (https=) | ||
| CN115103633B (zh) | 使用多种成像剂的成像方法 | |
| RU2014114119A (ru) | Биспецифические анти-egfr/анти igf-1r-антитела | |
| SI2905335T1 (en) | Anti-human dlk-1 antibody having anti-tumor activity in vivo | |
| SG189095A1 (en) | Compositions and methods for treating neoplasia | |
| Kaunitz | Development of monoclonal antibodies: the dawn of mAb rule |